- Home
- CDT vs APM Comparison
CDT vs APM Comparison
Compare CDT & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- APM
- Stock Information
- Founded
- CDT 2019
- APM 2010
- Country
- CDT United States
- APM United Kingdom
- Employees
- CDT N/A
- APM N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CDT Health Care
- APM Health Care
- Exchange
- CDT Nasdaq
- APM Nasdaq
- Market Cap
- CDT 10.9M
- APM 9.8M
- IPO Year
- CDT N/A
- APM 2018
- Fundamental
- Price
- CDT $0.11
- APM $0.71
- Analyst Decision
- CDT
- APM
- Analyst Count
- CDT 0
- APM 0
- Target Price
- CDT N/A
- APM N/A
- AVG Volume (30 Days)
- CDT 34.8M
- APM 61.0K
- Earning Date
- CDT 11-14-2024
- APM 12-20-2024
- Dividend Yield
- CDT N/A
- APM N/A
- EPS Growth
- CDT N/A
- APM N/A
- EPS
- CDT N/A
- APM N/A
- Revenue
- CDT N/A
- APM $431,378.00
- Revenue This Year
- CDT N/A
- APM $157,729.10
- Revenue Next Year
- CDT N/A
- APM N/A
- P/E Ratio
- CDT N/A
- APM N/A
- Revenue Growth
- CDT N/A
- APM N/A
- 52 Week Low
- CDT $0.08
- APM $0.46
- 52 Week High
- CDT $7.83
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- CDT 52.44
- APM 24.01
- Support Level
- CDT $0.08
- APM $0.46
- Resistance Level
- CDT $0.10
- APM $0.79
- Average True Range (ATR)
- CDT 0.02
- APM 0.13
- MACD
- CDT 0.00
- APM -0.04
- Stochastic Oscillator
- CDT 33.24
- APM 22.01
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.